サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1758980

個別化医療における生成AI（ジェネレーティブAI）の世界市場

Generative Artificial Intelligence (AI) in Personalized Medicine

出版日
ページ情報
英文 140 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.02円
個別化医療における生成AI（ジェネレーティブAI）の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

個別化医療における生成AI（ジェネレーティブAI）の世界市場は2030年までに9億1,920万米ドルに達する見込み

2024年に2億5,920万米ドルと推定された個別化医療における生成AI（ジェネレーティブAI）の世界市場は、2030年には9億1,920万米ドルに達し、分析期間2024-2030年のCAGRは23.5％で成長すると予測されます。本レポートで分析したセグメントの1つであるオンプレミスデプロイメントは、CAGR 21.0％を記録し、分析期間終了時には5億6,500万米ドルに達すると予測されます。クラウドベースデプロイメントセグメントの成長率は、分析期間中CAGR 28.2%と推定されます。

米国市場は6,810万米ドルと推定、中国はCAGR 22.4％で成長予測

米国の個別化医療における生成AI（ジェネレーティブAI）市場は、2024年に6,810万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 22.4%で推移し、2030年には1億4,100万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ21.1％と20.5％と予測されています。欧州では、ドイツがCAGR約16.4%で成長すると予測されています。

世界の「個別化医療における生成AI（ジェネレーティブAI）」市場- 主要動向と促進要因のまとめ

ジェネレーティブAIと個別化医療の融合が勢いを増す理由とは？

ジェネレーティブ人工知能（AI）の個別化医療への統合は、ヘルスケアのパラダイムシフトを象徴するものであり、計算イノベーション、ゲノム科学、患者中心のケアモデルの融合によって急速に推進されています。ジェネレーティブAIは、合成バイオマーカープロファイル、治療シミュレーション、薬物分子構造など、新しいデータ出力を作成できるモデルを含み、医療介入を個人レベルに合わせて調整する上で重要な役割を果たしています。この動向は、ゲノム配列、電子カルテ（EHR）、画像ファイル、患者のライフスタイルデータなど、多次元ヘルスケアデータの急激な増加によって促進されています。その結果、AIシステムは、かつてない精度で病気の進行や治療結果をシミュレーションする予測モデルを生成できるようになりました。病院や研究機関は、こうした機能を活用して診断を精緻化し、ケアプランを個別化し、臨床ワークフローを合理化しています。ヘルスケア提供を支えるデジタルインフラも、プラットフォーム間の相互運用性の向上や、患者の安全性を確保しながらイノベーションを促進する規制の枠組みに支えられ、AIアプリケーションに対応できるよう進化しています。さらに、北米やアジア太平洋の一部などデータが豊富な地域では、強固なバイオテクノロジーのエコシステムと資金調達の支援体制に後押しされ、AIの導入が急増しています。これらの要素が相まって、ヘルスケアのバリューチェーンが再構築され、ジェネレーティブAIが個別化医療の進化における礎となる技術として位置づけられています。

ジェネレーティブAIによって創薬はどのように変革されるのか？

個別化医療におけるジェネレーティブAIの最も破壊的な影響の一つは、AIが医薬品の設計、試験、承認方法を根本的に変えつつある創薬開発分野で観察されます。従来の創薬は資源集約的で時間がかかり、新薬の上市には10年以上と数十億米ドルの投資を必要とすることが多いです。生成モデル、特に変分オートエンコーダ（VAE）、トランスフォーマー、拡散モデルなどのアーキテクチャ上に構築されたモデルは、イン・シリコで何千もの潜在化合物を迅速に生成・評価することができ、研究開発の初期段階を劇的に短縮することができます。これらのモデルは、患者固有の遺伝子変異やバイオマーカーに合致する薬剤候補を特定するのに特に効果的で、個別化医療の基本原則に合致しています。さらにAIは、異なる分子がヒトのタンパク質とどのように相互作用するかをシミュレートしたり、集団固有のデータに基づいて副作用の可能性を予測し、医薬品の安全性プロファイルを改善することができます。新興企業も製薬大手も同様に、AIファーストのパイプラインを採用し、希少な遺伝性疾患など、従来の薬剤モデルが経済的に実行不可能なニッチな疾患をターゲットにしています。ハイテク企業と製薬企業のパートナーシップは、この動向を加速させる中心的存在となっており、多くの場合、ジョイントベンチャーや専用のAI創薬プラットフォームが誕生しています。知的財産もまた進化しており、AIによって生み出された化合物は、特許性に関する既存の枠組みに課題しています。規制機関は、AIが開発した治療法をより迅速に検証できるよう、適応性のあるガイドラインで対応しています。総じて、このような技術シフトにより、個別化治療薬の開発はこれまで以上に機敏に、コスト効率よく、正確に行われるようになっています。

この市場の形成において患者とヘルスケアプロバイダーはどのような役割を果たすのか？

個別化医療におけるジェネレーティブAIの広範な採用は、技術的な準備の機能だけでなく、患者、医療提供者、ヘルスケアシステムの行動変化を反映しています。現代の患者は、ウェアラブルやモバイルアプリを通じて自身の健康データにアクセスできるようになり、カスタマイズされたケアソリューションへの需要が高まっています。彼らは、独自の遺伝子やライフスタイルのプロファイルを反映した精密治療を求める傾向が強く、AIベースの診断・治療ツールのための肥沃な市場を作り出しています。同時に、ヘルスケアプロバイダーはAIを活用した意思決定支援システムを統合し、個別化された治療勧告の生成、治療結果のシミュレーション、さらには個別化された臨床文書の作成を行うようになっています。これにより、医師はより多くの情報に基づき、データに裏打ちされた意思決定を行うことができるため、臨床の生産性が向上し、患者の転帰が改善されます。システムの観点からは、病院や診療所は、個別化医療の成功に不可欠なリアルタイムのマルチソース・データ・フュージョンを可能にするAI統合電子カルテ・システムへの移行を進めています。保険会社も適応を始めており、AIを活用して個別化医療プランや予測リスク・モデルの引き受けを行っています。一方、学術機関は医療トレーニングプログラムにAIモジュールを組み込んでおり、将来の医療専門家がこのAI拡張環境で活動できるよう準備しています。パーソナライズされたAI対応ケア提供への集団的なシフトは、個別化されたリスク評価を通じて予防ケアと慢性疾患管理を促進する公衆衛生イニシアティブによってさらに強化されています。このようなエコシステム全体の変化は、消費者の期待と技術的能力の間の整合性が高まっていることを示しており、医療のパーソナライゼーションにおけるジェネレーティブAIの役割を確固たるものにしています。

個別化医療におけるジェネレーティブAIの世界市場需要急増の要因は？

個別化医療におけるジェネレーティブAI市場の成長は、技術の進化、エンドユーザーの拡大、システムの変革に直結するいくつかの要因によってもたらされています。第一に、ゲノミクス、トランスクリプトミクス、プロテオミクス、患者履歴などの大規模かつ高解像度のデータセットが利用可能になったことで、ジェネレーティブモデルにとって理想的なトレーニング環境が構築され、臨床的に関連性の高い洞察を生み出す能力が強化されました。第二に、全ゲノムシーケンシングと分子診断のコストが低下したことで、利用者層が大幅に拡大し、より多くの人々が個別化医療にアクセスできるようになりました。技術面では、クラウドインフラ、エッジコンピューティング、大規模言語モデル（LLM）アーキテクチャの急速な進歩により、膨大な生物医学データセットをリアルタイムで処理することが可能になりました。腫瘍学、神経学、免疫学などの最終用途分野では、個別化された治療経路で疾患サブタイプをターゲットとし、臨床効果の向上と副作用の軽減につながるジェネレーティブAIの統合が進んでいます。さらに、製薬会社やバイオテクノロジー企業は、パイプラインの開発を加速し、研究開発のオーバーヘッドを削減するために、AIとのコラボレーションに多額の投資を行っています。臨床試験の最適化も重要な推進力であり、AIが生成した仮想コホートが転帰のシミュレーションに使用され、大規模な患者募集への依存を減らしています。特に米国、中国、ドイツ、韓国のイノベーションハブでは、政府助成金、ベンチャーキャピタルの動向、官民イニシアチブがこの傾向を強めています。規制環境もまた、AIベースの申請に対応できるよう進化しており、より迅速な納期と試験デザインの柔軟性を提供しています。最後に、個別化されたケアプランに対する患者の嗜好の高まりは、AIが生成するアウトプットに対する臨床医の信頼と相まって、ヘルスケア・エコシステム全体での採用に拍車をかけています。これらの市場促進要因を総合すると、個別化医療におけるジェネレーティブAIアプリケーションの世界市場は堅調に拡大しています。

セグメント

デプロイメント（オンプレミスデプロイメント、クラウドベースデプロイメント）、アプリケーション（病院＆クリニックアプリケーション、外来手術センターアプリケーション、その他アプリケーション）

調査対象企業の例

  • Ada Health
  • Antidote AI
  • BenevolentAI
  • BioSymetrics
  • Berg Health
  • BioAge Labs
  • Blackford Analysis
  • Brightseed
  • CloudMedx
  • Deep Genomics
  • Enara Bio
  • Exscientia
  • GNS Healthcare
  • Helium Health
  • Insilico Medicine
  • IBM Watson Health
  • Kheiron Medical
  • LifeOmic
  • Lunit
  • Medtronic AI

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP36992

Global Generative Artificial Intelligence (AI) in Personalized Medicine Market to Reach US$919.2 Million by 2030

The global market for Generative Artificial Intelligence (AI) in Personalized Medicine estimated at US$259.2 Million in the year 2024, is expected to reach US$919.2 Million by 2030, growing at a CAGR of 23.5% over the analysis period 2024-2030. On-Premise Deployment, one of the segments analyzed in the report, is expected to record a 21.0% CAGR and reach US$565.0 Million by the end of the analysis period. Growth in the Cloud-based Deployment segment is estimated at 28.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.1 Million While China is Forecast to Grow at 22.4% CAGR

The Generative Artificial Intelligence (AI) in Personalized Medicine market in the U.S. is estimated at US$68.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$141.0 Million by the year 2030 trailing a CAGR of 22.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 21.1% and 20.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.4% CAGR.

Global "Generative Artificial Intelligence (AI) in Personalized Medicine" Market - Key Trends & Drivers Summarized

Why Is the Intersection of Generative AI and Personalized Medicine Gaining Momentum?

The integration of generative artificial intelligence (AI) into personalized medicine represents a paradigm shift in healthcare, one that is being rapidly propelled by the convergence of computational innovation, genomic science, and patient-centered care models. Generative AI, which includes models capable of creating novel data outputs-such as synthetic biomarker profiles, treatment simulations, or drug molecule structures-has found a critical role in tailoring medical interventions to the individual level. This trend is being catalyzed by the exponential growth of multi-dimensional healthcare data, including genomic sequencing, electronic health records (EHRs), imaging files, and patient lifestyle data. As a result, AI systems can now generate predictive models that simulate disease progression or treatment outcomes with unprecedented accuracy. Hospitals and research institutions are leveraging these capabilities to refine diagnosis, personalize care plans, and streamline clinical workflows. The digital infrastructure underpinning healthcare delivery is also evolving to accommodate AI applications, supported by increasing interoperability between platforms and regulatory frameworks that promote innovation while ensuring patient safety. Additionally, data-rich regions such as North America and parts of Asia-Pacific are witnessing a surge in AI adoption, driven by their robust biotechnology ecosystems and supportive funding landscapes. Together, these elements are reshaping the healthcare value chain and positioning generative AI as a cornerstone technology in the evolution of personalized medicine.

How Is Drug Discovery Being Transformed by Generative AI?

One of the most disruptive impacts of generative AI in personalized medicine is observed in the drug discovery and development sector, where AI is fundamentally altering how pharmaceutical products are designed, tested, and approved. Traditional drug discovery is resource-intensive and time-consuming, often requiring over a decade and billions in investment to bring a new drug to market. Generative models-especially those built on architectures like variational autoencoders (VAEs), transformers, and diffusion models-can rapidly generate and evaluate thousands of potential compounds in silico, dramatically compressing the early stages of R&D. These models are particularly effective in identifying drug candidates that align with a patient's unique genetic mutations or biomarkers, thereby aligning with the core principles of personalized medicine. Further, AI can simulate how different molecules interact with human proteins or predict the likelihood of side effects based on population-specific data, improving drug safety profiles. Startups and pharma giants alike are adopting AI-first pipelines to target niche conditions, such as rare genetic diseases, where conventional drug models are not economically viable. Partnerships between tech companies and pharmaceutical firms have become central to accelerating this trend, often resulting in joint ventures or dedicated AI drug discovery platforms. Intellectual property is also evolving, as AI-generated compounds challenge existing frameworks for patentability. Regulatory bodies are responding with adaptive guidelines, allowing faster validation of AI-developed therapies. Altogether, this technological shift is making the development of personalized therapeutics more agile, cost-efficient, and precise than ever before.

What Role Do Patients and Healthcare Providers Play in Shaping This Market?

The broader adoption of generative AI in personalized medicine is not only a function of technological readiness but also reflects changing behaviors among patients, providers, and healthcare systems. Modern patients, increasingly empowered by access to their own health data through wearables and mobile apps, are driving demand for customized care solutions. They are more inclined to seek out precision treatments that reflect their unique genetic and lifestyle profiles, creating a fertile market for AI-based diagnostic and therapeutic tools. At the same time, healthcare providers are integrating AI-powered decision support systems that generate individualized treatment recommendations, simulate treatment outcomes, and even produce personalized clinical documentation. This enhances clinical productivity and improves patient outcomes, as physicians can make more informed, data-backed decisions. From a systems perspective, hospitals and clinics are transitioning to AI-integrated electronic health record systems that enable real-time, multi-source data fusion-crucial for the success of personalized medicine. Insurers are also beginning to adapt, using AI to underwrite personalized health plans and predictive risk models. Meanwhile, academic institutions are incorporating AI modules into medical training programs, preparing future healthcare professionals to operate in this AI-augmented environment. The collective shift toward personalized, AI-enabled care delivery is further reinforced by public health initiatives that promote preventive care and chronic disease management through individualized risk assessments. These ecosystem-wide changes indicate a growing alignment between consumer expectations and technological capabilities, solidifying generative AI’s role in the personalization of medicine.

What’s Fueling the Surge in Global Market Demand for Generative AI in Personalized Medicine?

The growth in the generative AI in personalized medicine market is driven by several factors directly tied to technological evolution, end-user expansion, and systemic transformation. First, the availability of large-scale, high-resolution datasets-from genomics, transcriptomics, proteomics, and patient histories-creates the ideal training environment for generative models, enhancing their ability to produce clinically relevant insights. Second, the decreasing cost of whole-genome sequencing and molecular diagnostics has significantly expanded the user base, making personalized care accessible to a broader population. On the technological front, rapid advancements in cloud infrastructure, edge computing, and large language model (LLM) architectures have made it feasible to process vast biomedical datasets in real time. End-use sectors such as oncology, neurology, and immunology are increasingly integrating generative AI to target disease subtypes with personalized treatment pathways, leading to better clinical efficacy and reduced adverse effects. Additionally, pharma and biotech companies are investing heavily in AI collaborations to accelerate pipeline development and reduce R&D overhead. Clinical trial optimization is another critical driver, with AI-generated virtual cohorts being used to simulate outcomes and reduce dependency on large-scale patient recruitment. Government grants, venture capital flows, and public-private initiatives are reinforcing this trend, especially in innovation hubs across the U.S., China, Germany, and South Korea. Regulatory environments are also evolving to accommodate AI-based submissions, offering faster turnaround times and greater flexibility in trial designs. Lastly, growing patient preference for individualized care plans, coupled with clinician trust in AI-generated outputs, is fueling adoption across healthcare ecosystems. Collectively, these drivers point to a robust and expanding global market for generative AI applications in personalized medicine.

SCOPE OF STUDY:

The report analyzes the Generative Artificial Intelligence (AI) in Personalized Medicine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Deployment (On-Premise Deployment, Cloud-based Deployment); Application (Hospitals & Clinics Application, Ambulatory Surgery Centers Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Ada Health
  • Antidote AI
  • BenevolentAI
  • BioSymetrics
  • Berg Health
  • BioAge Labs
  • Blackford Analysis
  • Brightseed
  • CloudMedx
  • Deep Genomics
  • Enara Bio
  • Exscientia
  • GNS Healthcare
  • Helium Health
  • Insilico Medicine
  • IBM Watson Health
  • Kheiron Medical
  • LifeOmic
  • Lunit
  • Medtronic AI

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Generative Artificial Intelligence (AI) in Personalized Medicine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advancements in Generative AI Algorithms Drive Precision Treatment Planning and Custom Drug Design
    • Integration of Multi-Omics Data Sets Strengthens Business Case for AI-Enabled Personalization
    • Rising Investment in Digital Health Accelerates Adoption of Generative AI in Clinical Decision Support
    • Partnerships Between Biotech Firms and AI Startups Generate Breakthrough Innovations in Therapy Design
    • Use of AI-Generated Digital Twins Throws Spotlight on Predictive Patient Response Modeling
    • Demand for Real-Time Adaptive Treatment Algorithms Expands Addressable Market for AI Tools
    • Ethical and Regulatory Frameworks Shape Responsible AI Integration in Personalized Medicine
    • Increased Use of Generative AI in Rare Disease Discovery Propels Pharmaceutical Interest
    • Data Privacy and Model Transparency Requirements Drive Investment in Explainable AI Systems
    • Growing Clinical Trial Complexity Sustains AI Adoption in Virtual Patient Recruitment and Simulation
    • Interoperability Between AI Models and EHR Systems Generates Hospital-Level Deployment Opportunities
    • Healthcare Payers Shift Toward Value-Based Care Supports Investment in Outcome-Driven AI Tools
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Generative Artificial Intelligence (AI) in Personalized Medicine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for On-Premise Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for On-Premise Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Cloud-based Deployment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Cloud-based Deployment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals & Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals & Clinics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Ambulatory Surgery Centers Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 52: Rest of Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Rest of Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Generative Artificial Intelligence (AI) in Personalized Medicine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 60: Rest of World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - On-Premise Deployment and Cloud-based Deployment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Deployment - Percentage Breakdown of Value Sales for On-Premise Deployment and Cloud-based Deployment for the Years 2025 & 2030
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of World 6-Year Perspective for Generative Artificial Intelligence (AI) in Personalized Medicine by Application - Percentage Breakdown of Value Sales for Hospitals & Clinics Application, Ambulatory Surgery Centers Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION